← Leaderboards
Kenneth J McIntosh
Children'S Hospital Boston
$8,678,025
Attributed
$8,678,025
Total exposure
15
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–07$2M$1.5M$1M$500K$0
'05
'06
'07
Funding mix
By agency
NIH$8,678,025 · 15
By mechanism
U01$8,063,149 · 1
M01$614,876 · 14
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectPediatric AidsAids TherapyClinical ResearchHiv InfectionsHuman Therapy EvaluationClinical Trial Phase IChild (0-11)Combination ChemotherapyVertical TransmissionPharmacokineticsProtease InhibitorReverse Transcriptase InhibitorsAntiaids AgentLongitudinal Human StudyBehavioral /Social Science Research TagDisease /Disorder Proneness /RiskOpportunistic InfectionsStavudineVirus Infection MechanismDrug Screening /EvaluationMicroorganism Disease ChemotherapyNevirapineClinical Trials
Grant awards (41)
Boston Pediatric AIDS Clinical Trials Unit$874,670
U01 · FY2007 · AI · contact PI
PACTG 1038: HIGH DOSE LOPINAVIR/RITONAVIR W/ OR W/OUT SAQUINAVIR IN HIV$13,032
M01 · FY2007 · RR · contact PI
Boston Pediatric AIDS Clinical Trials Unit$525,156
U01 · FY2006 · AI · contact PI
PACTG 1038:PHASE I/II HIGH DOSE LOPINAVIR/RITONAVIR WITH OR WITHOUT SAQUINAVIR I$136,012
M01 · FY2006 · RR · contact PI
Boston Pediatric AIDS Clinical Trials Unit$1,000,257
U01 · FY2005 · AI
Boston Pediatric AIDS Clinical Trials Unit$981,946
U01 · FY2004 · AI
PACTG-1024 Eval. of the Immunogenicity of pneumococcal conjugate vaccine &rout.$2,081
M01 · FY2004 · RR
A COLLABORATIVE STUDY OF VERTICAL TRANSMISSION OF HIV (WITS IV)$416
M01 · FY2004 · RR
Boston Pediatric AIDS Clinical Trials Unit$1,168,600
U01 · FY2003 · AI
Boston Pediatric AIDS Clinical Trials Unit$1,163,520
U01 · FY2002 · AI
COLLABORATIVE PROSPECTIVE STUDY OF VERTICAL TRANSMISSION OF HIV$28,750
M01 · FY2002 · RR
LATE OUTCOMES OF PEDIATRIC INFECTION$28,750
M01 · FY2002 · RR
ACTG356--ZDV/3TC/NEVIRAPINE &ZDV/3TC/NEVIRAPINE/159U89 COMBINATION THERAPY$28,750
M01 · FY2002 · RR
ACTG 382--PHASE I/II, OPEN LABEL, AUC CONTROLLED STUDY DMP 266$28,750
M01 · FY2002 · RR
COMBINATION REGIMENS OF PROTEASE INHIBITOR, NRTI, NNRTI$0
M01 · FY2002 · RR
RECOMBINANT IL-2 IN HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
PEDIATRIC ACTG--ACTU$1,184,741
U01 · FY2001 · AI
COLLABORATIVE PROSPECTIVE STUDY OF VERTICAL TRANSMISSION OF HIV$28,750
M01 · FY2001 · RR
LATE OUTCOMES OF PEDIATRIC INFECTION$28,750
M01 · FY2001 · RR
LATE OUTCOMES OF PEDIATRIC INFECTION$28,750
M01 · FY2001 · RR
COLLABORATIVE PROSPECTIVE STUDY OF VERTICAL TRANSMISSION OF HIV$28,750
M01 · FY2001 · RR
ACTG356--ZDV/3TC/NEVIRAPINE &ZDV/3TC/NEVIRAPINE/159U89 COMBINATION THERAPY$28,750
M01 · FY2001 · RR
ACTG356--ZDV/3TC/NEVIRAPINE &ZDV/3TC/NEVIRAPINE/159U89 COMBINATION THERAPY$28,750
M01 · FY2001 · RR
ACTG 382--PHASE I/II, OPEN LABEL, AUC CONTROLLED STUDY DMP 266$28,750
M01 · FY2001 · RR
ACTG 382--PHASE I/II, OPEN LABEL, AUC CONTROLLED STUDY DMP 266$28,750
M01 · FY2001 · RR
COMBINATION REGIMENS OF PROTEASE INHIBITOR, NRTI, NNRTI$0
M01 · FY2001 · RR
RECOMBINANT IL-2 IN HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
RECOMBINANT IL-2 IN HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
COMBINATION REGIMENS OF PROTEASE INHIBITOR, NRTI, NNRTI$0
M01 · FY2001 · RR
PEDIATRIC ACTG--ACTU$1,164,259
U01 · FY2000 · AI
COLLABORATIVE PROSPECTIVE STUDY OF VERTICAL TRANSMISSION OF HIV$28,750
M01 · FY2000 · RR
LATE OUTCOMES OF PEDIATRIC INFECTION$28,750
M01 · FY2000 · RR
ACTG 382--PHASE I/II, OPEN LABEL, AUC CONTROLLED STUDY DMP 266$28,750
M01 · FY2000 · RR
ACTG356--ZDV/3TC/NEVIRAPINE &ZDV/3TC/NEVIRAPINE/159U89 COMBINATION THERAPY$28,750
M01 · FY2000 · RR
ACTG 338--NOVEL ANTIRETROVIRAL THERAPY IN HIV INFECTED CHILDREN$667
M01 · FY2000 · RR
PRAM 2: PHASE I/II RANDOMIZED MULTICENTER PROTOCOL COMPARING 4 ANTIRETROVIRALS$667
M01 · FY2000 · RR
RANDOMIZED STUDY OF ATOVAQUONE AND AZITHROMYCIN AS COMPARED TO TMP/SMZ$667
M01 · FY2000 · RR
SAFETY, PHARMACOKINETICS &EFFICACY OF INDINAVIR IN COMBINATION W/ STAVUDINE/LA$667
M01 · FY2000 · RR
PHARMACOKINETIC AND TOLERANCE STUDY OF ORAL GANCICLOVIR IN HIV INFECTED CHILDREN$667
M01 · FY2000 · RR
COMBINATION REGIMENS OF PROTEASE INHIBITOR, NRTI, NNRTI$0
M01 · FY2000 · RR
RECOMBINANT IL-2 IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR